Table 1.
Demographic/biopsy data of UCSD patient cohort with evaluable TMBs for multiple biopsies and clinical data
| Factor | Item | Value [95% CI] | ||
|---|---|---|---|---|
| Average time between biopsies (days) | 722 [621–821] | |||
| Average TMB difference (mutations/Mb) | 0.583 [− 0.900–2.064] | |||
| Age at first biopsy (years) | 57.36 [55.22–59.50] | |||
| Gender | Men | 106 (52.48%) | ||
| Women | 96 (47.52%) | |||
| Diagnoses | Colorectal adenocarcinoma | 29 (14.36%) | ||
| Lung adenocarcinoma | 20 (9.901%) | |||
| Breast invasive ductal adenocarcinoma | 10 (4.950%) | |||
| Metastatic (any primary) | 99 (49.00%) | |||
| Biopsy sites | First biopsy | Last biopsy | ||
| Lung | 22 (10.89%) | Liver | 33 (16.34%) | |
| Colon | 19 (9.406%) | Lung | 20 (9.901%) | |
| Soft Tissue | 16 (7.921%) | Lymph Node | 16 (7.921%) | |
| Bone Marrow | 11 (5.446%) | Bone Marrow | 14 (6.931%) | |
| Liver | 11 (5.446%) | Colon | 12 (5.941%) | |
| Others | 123 (60.89%) | Others | 107 (52.97%) | |
| Immunotherapy (checkpoint) | Number receiving immunotherapy between biopsies | 55 (27.23%) | ||
| Number NOT receiving immunotherapy | 147 (72.77%) | |||
| TMB measured | High at first biopsy (≥ 20 mutations/Mb) | 10 (4.950%) | ||
| Intermediate at first biopsy (5 < TMB ≤ 19 mutations/Mb) | 49 (24.26%) | |||
| Low at first biopsy (≤ 5 mutations/Mb) | 143 (70.79%) | |||
| High at second biopsy (≥ 20 mutations/Mb) | 13 (6.436%) | |||
| Intermediate at second biopsy (5 < TMB ≤ 19 mutations/Mb) | 50 (24.75%) | |||
| Low at second biopsy (≤ 5 mutations/Mb) | 139 (68.81%) | |||
Patients in the UCSD cohort (N = 202) tend to be older and are roughly evenly distributed between men and women. Almost half (49%) of the patients have metastatic cancer. 55 of them (27.23%) received immunotherapy between their first and last biopsies, on average 722 days apart
Data derived from medical record; if tobacco or alcohol exposure not known, then patients not counted